Click to Enlarge Market Cap: $215M
Description from Yahoo! Finance
Celldex Therapeutics (NASDAQ:CLDX), a biopharmaceutical company, engages in the development, manufacture and commercialization of novel therapeutics for human healthcare. The company offers Rotarix for the treatment of rotavirus infection. Its clinical development program includes CDX-110 which is in Phase IIb clinical trial for the treatment of glioblastoma multiforme.
Click to Enlarge Technical Analysis
The stock also trades nicely above its 50- and 200-day moving averages and finds next support at its 50% and 61.8% retracement levels of its latest upswing. The 61.8% retracement level also coincides with the 50-day moving average.